title: In vivo selection of human tumor cells resistant to monoclonal antibody-Vinca alkaloid immunoconjugates.
abstract: UCLA-P3 human lung adenocarcinoma cells were grown in nude mice and given repetitive treatments of a monoclonal antibody-Vinca alkaloid immunoconjugate. Although this therapy resulted in a greater than 4-fold reduction in mean tumor mass of the established tumors, some animals experienced a reinitiation of tumor growth after cessation of conjugate treatment. Two such animals were treated again with high doses of monoclonal antibody-Vinca but one of the tumors was no longer regressed by the drug conjugate. The tumor was excised, enzymatically dissociated, and grown in tissue culture. Cultured cells were reimplanted in nude mice and subjected to further therapy with a monoclonal antibody-Vinca conjugate. The resulting tumors were also refractory to the immunoconjugate therapy. This cycle was repeated for a total of three times and resulted in the serial in vivo selection of three conjugate resistant variants. The mechanism responsible for the in vivo resistance of human tumor cells to the monoclonal antibody-Vinca immunoconjugate is unknown but does not appear to involve antigen modulation, altered tumor cell growth rate, or an apparent decrease in tumor targeting in vivo. The resistance was also not accompanied by any detectable elevation in multidrug resistance 1 mRNA or P-glycoprotein expression. Significantly, the resistance pattern was observed only in vivo and was not maintained by cells grown in vitro.
authors.affiliation: Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana 46285.
authors.forename: J J
authors.initials: JJ
authors.lastname: Starling
authors.forename: R S
authors.initials: RS
authors.lastname: Maciak
authors.forename: N A
authors.initials: NA
authors.lastname: Hinson
authors.forename: J
authors.initials: J
authors.lastname: Hoskins
authors.forename: B C
authors.initials: BC
authors.lastname: Laguzza
authors.forename: R A
authors.initials: RA
authors.lastname: Gadski
authors.forename: J
authors.initials: J
authors.lastname: Strnad
authors.forename: L
authors.initials: L
authors.lastname: Rittmann-Grauer
authors.forename: S V
authors.initials: SV
authors.lastname: DeHerdt
authors.forename: T F
authors.initials: TF
authors.lastname: Bumol
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000230:Adenocarcinoma / Q000188:drug therapy*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001667:Binding, Competitive; D015152:Blotting, Northern; D004351:Drug Resistance / Q000235:genetics; D004357:Drug Synergism; D005455:Fluorescent Antibody Technique; D000922:Immunotoxins / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000494:pharmacology; D008175:Lung Neoplasms / Q000188:drug therapy*; D008562:Membrane Glycoproteins / Q000096:biosynthesis; D051379:Mice; D008819:Mice, Nude; D012333:RNA, Messenger / Q000032:analysis; D014748:Vinca Alkaloids / Q000627:therapeutic use*
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000911:Antibodies, Monoclonal; D000922:Immunotoxins; D007376:Interleukin-2; D008562:Membrane Glycoproteins; D012333:RNA, Messenger; D014748:Vinca Alkaloids